Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples